Commit To Purchase Medicines At $21, Earn 11.9% Annualized Using Options
at The Street - Wed Dec 24, 11:17AM CST
Investors considering a purchase of Medicines Co shares, but cautious about paying the going market price of $26.67/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
MDCO: 27.06 (+0.21)
MacroGenics Inks Deal with J&J for Blood Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:00PM CST
MacroGenics, Inc. (MGNX) entered into a collaboration and license agreement with Johnson & Johnson for the development and commercialization of MGD011.
MGNX: 33.00 (+0.34), JNJ: 104.59 (+0.31), MDCO: 27.06 (+0.21), BMY: 59.15 (-0.01), FPRX: 26.12 (+0.07)
Alnylam Pharmaceuticals Continues To Post Encouraging Results
Stephen Simpson, CFA - at Seeking Alpha - Mon Dec 22, 11:15AM CST
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), ALXN: 181.96 (+3.09), SNY: 46.35 (+0.50)
FDA OKs Cubist antibiotic for serious infections
BY LINDA A. JOHNSON - AP - Fri Dec 19, 9:40PM CST
TRENTON, N.J. (AP) — The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.
MDCO: 27.06 (+0.21), MRK: 57.46 (+0.25)
Alnylam Announces Planned Departure of Chief Business Officer, Laurence Reid, Ph.D.
Business Wire - Fri Dec 19, 7:00AM CST
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that Laurence Reid, Ph.D., the company's Chief Business Officer, plans to resign from the company, effective December 31, 2014. Dr. Reid will be joining Third Rock Ventures (TRV) as an Entrepreneur-in-Residence, and is expected to become a Chief Executive Officer for a TRV portfolio company in the future. Alnylam will initiate an external search to identify a new Chief Business Officer.
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), MRK: 57.46 (+0.25)
SciClone to promote two Medicines Company products in China
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:50AM CST
MDCO: 27.06 (+0.21), SCLN: 8.64 (+0.16)
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
Business Wire - Thu Dec 18, 6:00AM CST
The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focused on hospital care, and SciClone Pharmaceuticals (Nasdaq: SCLN), a U.S. based, China focused specialty pharmaceutical company, today announced the establishment of a strategic partnership for two cardiovascular products in China. The partnership includes an agreement granting SciClone a license and the exclusive rights in China to promote two products of The Medicines Company:
MDCO: 27.06 (+0.21), SCLN: 8.64 (+0.16)
Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 4:50PM CST
Alnylam (ALNY) announced a strategy for developing its RNAi therapeutics in three strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic disease and hepatic infectious disease.
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), AMGN: 160.67 (+3.15), SNY: 46.35 (+0.50)
It's Not the Zombie Apocalypse, but Killer Superbugs Could Be on the Way
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 14, 6:44AM CST
Hospital-associated MRSA bacteria. Source: NIAID via Flickr . Humans are pretty darn lucky. We're surrounded on a daily basis by a number of things that could potentially kill us , including bacteria and viruses, yet our immune system has...
ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MDCO: 27.06 (+0.21), MRK: 57.46 (+0.25)
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines
PR Newswire - Fri Dec 12, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Akorn Inc. (NASDAQ: AKRX), and The Medicines Company (NASDAQ: MDCO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 11, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,596.34, up 0.36% and the NASDAQ Composite closed at 4,708.16, up 0.52%. The S&P 500 finished the session 0.45% higher at 2,035.33. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 27.06 (+0.21), AKRX: 36.47 (+0.43), MRK: 57.46 (+0.25), PFE: 31.42 (-0.03), ABBV: 66.21 (+1.86)
Alnylam earns milestone on start of Phase 1 hypercholesterolemia trial
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 8:06AM CST
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21)
Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Thu Dec 11, 7:01AM CST
--- Companies Expect to Present Initial Clinical Results in Mid-2015 -
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21)
The Medicines Company to Participate in Oppenheimer 25th Annual Healthcare Conference
Business Wire - Mon Dec 08, 9:15AM CST
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on Wednesday, December 10th at 9:10 AM EST.
MDCO: 27.06 (+0.21)
Upgrade Alert for Medicines Co (MDCO)
Comtex SmarTrend(R) - Thu Nov 20, 7:04AM CST
Medicines Co (NASDAQ:MDCO) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $24.99 on volume of 419,000 shares, below average daily volume of 948,000. The Medicines Company develops products that improve specialized care. The Company markets Angiomax, an anticoagulant approved in the United States and other countries for use in patients undergoing coronary angioplasty procedures.
MDCO: 27.06 (+0.21)
The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients
Business Wire - Sun Nov 16, 9:30AM CST
The Medicines Company (NASDAQ:MDCO) today presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association's Annual Scientific Sessions in Chicago.
MDCO: 27.06 (+0.21)
The Medicines Company to Present New Data on Investigational Lipid-Modifying Agent MDCO-216 and Investigational Antiplatelet Agent Cangrelor at 2014 American Heart Association (AHA) Annual Scientific Sessions in Chicago
Business Wire - Fri Nov 14, 9:32AM CST
The Medicines Company (NASDAQ:MDCO) will present new data from studies involving the investigational lipid-modifying agent MDCO-216 and investigational intravenous antiplatelet agent cangrelor during the annual American Heart Association (AHA) Scientific Sessions in Chicago, November 15-19. The oral presentations and abstracts involve clinical data and analyses from two core areas of cardiovascular medicine for the Company: lipid-modifying therapies and acute cardiovascular care.
MDCO: 27.06 (+0.21)
The Medicines Company to Participate in Credit Suisse Healthcare Conference
Business Wire - Tue Nov 11, 10:07AM CST
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Credit Suisse Healthcare Conference in Phoenix, AZ on Wednesday, November 12th at 1:00 PM Mountain Time / 3:00 PM Eastern Time.
MDCO: 27.06 (+0.21)
Health Economic Data on The Medicines Company's Infectious Disease and Cardiology Portfolios to be Presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Business Wire - Fri Nov 07, 2:00PM CST
The Medicines Company (NASDAQ:MDCO) today announced that data from two health economics analyses will be presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) being held in Amsterdam, November 8-12. The abstracts involve analyses from two core areas of hospital focus for The Medicines Company: serious infectious disease care and acute cardiovascular care.
MDCO: 27.06 (+0.21)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), SNY: 46.35 (+0.50)
The Medicines Company Announces First Patient Enrollment in Phase 3 Studies of CARBAVANCE(TM) in Development for the Treatment of Serious Bacterial Infections Due to Gram-Negative Bacteria
Business Wire - Wed Nov 05, 5:30AM CST
The Medicines Company (NASDAQ:MDCO) today announced enrollment of the first patient in its Phase 3 clinical trial program for CARBAVANCE(TM) (meropenem/RPX7009), an investigational intravenous antibiotic under development for the treatment of serious bacterial infections due to gram-negative bacteria, particularly KPC (Klebsiella pneumoniae carbapenemase)-producing carbapenem-resistant Enterobacteriaceae (CRE).
MDCO: 27.06 (+0.21)